Nurulimab Biosimilar Monoclonal Antibody (CTLA-4) for Research

Cat No.: GMP-Bios-ab-382

Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nurulimab (also known as BCD 145) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for the treatment of cancer

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-382-1mg 1mg 3090

Size： 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name Nurulimab
TargetCTLA-4
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure5xj3:AB/5tru:HL/6jc2:HL
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesBiocad
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMalignant melanoma
Development Techna



About target - CTLA4

1. Protein Cytotoxic T-lymphocyte protein 4

2. Gene CTLA4

3. Organism Homo sapiens (Human)

Function
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.

Miscellaneous
The therapeutic antibody Ipilimumab competes for the binding site of the endogenous ligands CD80/B7-1, CD86/B7-2 and ICOSLG.